Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study.

[1]  T. Casale,et al.  Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma , 2017, Allergy.

[2]  W. Busse,et al.  Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO. , 2017, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[3]  I. Abraham,et al.  "Real-life" Effectiveness Studies of Omalizumab in Adult Patients with Severe Allergic Asthma: Meta-analysis. , 2017, The journal of allergy and clinical immunology. In practice.

[4]  R. Gangnon,et al.  Relationships among aeroallergen sensitization, peripheral blood eosinophils, and periostin in pediatric asthma development , 2017, The Journal of allergy and clinical immunology.

[5]  P. Gibson,et al.  Real‐life effectiveness of omalizumab in severe allergic asthma above the recommended dosing range criteria , 2016, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[6]  E. Bleecker,et al.  Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial , 2016, The Lancet.

[7]  W. Busse,et al.  Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial , 2016, The Lancet.

[8]  C. Lemière,et al.  Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels: A Randomized Phase 3 Study. , 2016, Chest.

[9]  E. Bateman,et al.  Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. , 2016, The Lancet. Respiratory medicine.

[10]  Bo Hu,et al.  Intrasubject Variability in Total IgE Levels in Patients with Moderate to Severe Persistent Allergic Asthma Over 1 Year. , 2016, The journal of allergy and clinical immunology. In practice.

[11]  R. Maciuca,et al.  Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies , 2015, Thorax.

[12]  E. Bateman,et al.  Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. , 2015, The Lancet. Respiratory medicine.

[13]  W. Busse,et al.  Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. , 2014, The Lancet. Respiratory medicine.

[14]  Ian D Pavord,et al.  Mepolizumab treatment in patients with severe eosinophilic asthma. , 2014, The New England journal of medicine.

[15]  H. Watz,et al.  Omalizumab in patients with allergic (IgE-mediated) asthma and IgE/bodyweight combinations above those in the initially approved dosing table. , 2014, Pulmonary pharmacology & therapeutics.

[16]  M. Barthwal,et al.  Real-world outcomes in patients receiving omalizumab for allergic asthma in India: Analysis by baseline IgE level , 2013 .

[17]  S. Spector,et al.  High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects. , 2013, The Journal of allergy and clinical immunology.

[18]  W. Busse,et al.  Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. , 2013, American journal of respiratory and critical care medicine.

[19]  J. Salleron,et al.  Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey , 2013, European Respiratory Journal.

[20]  S. de la Motte,et al.  Omalizumab Protects against Allergen- Induced Bronchoconstriction in Allergic (Immunoglobulin E-Mediated) Asthma , 2012, International Archives of Allergy and Immunology.

[21]  Ian D Pavord,et al.  Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial , 2012, The Lancet.

[22]  C. Brightling,et al.  A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma , 2012, European Respiratory Journal.

[23]  G. O'Connor,et al.  Asthma outcomes: pulmonary physiology. , 2012, The Journal of allergy and clinical immunology.

[24]  M. Blaiss,et al.  Asthma management and control in the United States: results of the 2009 Asthma Insight and Management survey. , 2012, Allergy and asthma proceedings.

[25]  Nicola A Hanania,et al.  Lebrikizumab treatment in adults with asthma. , 2011, The New England journal of medicine.

[26]  Margaret W Leigh,et al.  An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. , 2011, American journal of respiratory and critical care medicine.

[27]  W. Lincourt,et al.  Predictors of Uncontrolled Asthma in Adult and Pediatric Patients: Analysis of the Asthma Control Characteristics and Prevalence Survey Studies (ACCESS) , 2010, The Journal of asthma : official journal of the Association for the Care of Asthma.

[28]  Mark Kosinski,et al.  The minimally important difference of the Asthma Control Test. , 2009, The Journal of allergy and clinical immunology.

[29]  J. Bousquet,et al.  Predicting and evaluating response to omalizumab in patients with severe allergic asthma. , 2007, Respiratory medicine.

[30]  Craig A. Jones,et al.  Improvement of asthma control with omalizumab in 2 obese pediatric asthma patients. , 2006, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[31]  J. Hankinson,et al.  Standardisation of spirometry , 2005, European Respiratory Journal.

[32]  J. Donohue.  Minimal Clinically Important Differences in COPD Lung Function , 2005, COPD.

[33]  J. Bousquet,et al.  Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. , 2004, Chest.

[34]  Philip Marcus,et al.  Development of the asthma control test: a survey for assessing asthma control. , 2004, The Journal of allergy and clinical immunology.

[35]  J Zhang,et al.  What are minimal important changes for asthma measures in a clinical trial? , 1999, The European respiratory journal.

[36]  R. Pauwels,et al.  GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .

[37]  F. Martinez,et al.  Association of asthma with serum IgE levels and skin-test reactivity to allergens. , 1989, The New England journal of medicine.

[38]  F. Speizer,et al.  Epidemiology of chronic mucus hypersecretion and obstructive airways disease. , 1979, Epidemiologic reviews.